

REFERENCES

- Abenhaim, L.; Moride, Y.; Brenot, F.; Rich, S.; Benichou, J.; Kurz, X.; Higenbottam, T.; Oakley, C.; Wouters, E.; Aubier, M.; Simonneau, G. and Bégaud, B. (1996):** Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group. *N. Engl. J. Med.*, **335(9): 609-616.**
- Aguillón, J. C.; Cruzata, A.; Aravena, O.; Salazar, L.; Llanos, C. and Cuchacovich, M. (2006):** Could single-nucleotide polymorphisms (SNPs) affecting the tumour necrosis factor promoter be considered as part of rheumatoid arthritis evolution? *Immunobiology*, **211: 75–84.**
- Allen, E. (1922):** The oestrus cycle in the mouse. *Am. J. Anat.*, **30: 297-299.**
- Allison, A. C. (2000):** Immunosuppressive drugs: the first 50 years and a glance forward. *Immunopharmacology*, **47(2-3): 63-83.**
- Anundi, I.; Lahteenmaki, T.; Rundgren, M.; Moldeus, P. and Lindros, K. O. (1993):** Zonation of acetaminophen metabolism and cytochrome-P450 2E1-mediated toxicity studied in isolated periportal and perivenous hepatocytes. *Biochem. Pharmacol.*, **45: 1251-1259.**
- Arany, J. and Buisson, G. J. Du. (1982):** Sperm abnormalities and prenatal losses in mouse. *Stal. Sci. Tech. Anim. Lab.*, **7(1): 25-29.**

- Arora, A. and Scholar, E. M. (2005):** Role of tyrosine kinase inhibitors in cancer therapy. **J. Pharmacol. Exp. Ther.**, **315(3): 971-979.**
- Awwad, M. H. (2003):** Molecular identification of *Biomphalaria alexandrina* and *Bulinus truncates* using PCR-RFLPs of action gene. **J. Egypt, Acad. Soc. Environ. Develop.**, **3: 39-52.**
- Azab, M. S. (2003):** Studies on some molecular biological aspects of *Tilapia* fish in Egypt. **M.Sc. Thesis, Fac. Sci., Benha univ., 166pp.**
- Barak, A.; Morse, L. S. and Schwab, I. (2004):** Leflunomide (Arava)-induced cystoid macular oedema. **Rheumatology**, **43: 246-248.**
- Bartlett, R. R.; Brendel, S.; Zielinski, T. and Schorlemmer, H. U. (1996):** Leflunomide, an immunorestoring drug for the therapy of autoimmune disorders, especially rheumatoid arthritis. **Transplant. Proc.**, **28(6): 3074–3078.**
- Bartlett, R.R.; Dimitrijevic, M.; Matar, T.; Zielinski, T.; Bermann, T.; Rude, E.; Thoenes, G.H.; Kuchle, C.C.A.; Schorlemer, H.-U.; Bremer, E.; Finnegan, A. and Schleyerbach, R. (1991):** Leflunomide (HWA486), a novel immunomodulating compound for the treatment of autoimmune disorders and reactions leading to transplantation rejection. **Agents Actions**, **32: 10-21.**
- Baum, D. (2008):** Reading a Phylogenetic Tree: The Meaning of Monophyletic Groups. **Ph.D. Thesis, Dept. of Botany, University of Wisconsin, 430 Lincoln Ave., Madison, WI.**

- Beaune, P.; Dansette, P. M.; Mansuy, D.; Kiffel, L.; Finck, A. C.; Leroux, J. P. and Homberg, J. C. (1987):** Human anti-endoplasmic reticulum autoantibodies appearing in a druginduced hepatitis are directed against a human cytochrome P450 that hydroxylates the drug. **Proc. Natl. Acad. Sci., 84: 551–555.**
- Belgi, A. and Sowden, J. (2005):** Leflunomide-induced pseudoporphyria. **J. Am. Acad. Dermatol., 52(3): 54.**
- Billera, L. J.; Holmes, S. P. and Vogtmann, K. (2001):** Geometry of the Space of Phylogenetic Trees. **Adv. Appl. Math., 27: 733–767.**
- Billet, F. S. and Wild, A. E. (1975):** Practical studies of animal development. **Printed in G.B. by Willmer brothers LTD. Birkenhead, PP: 185-303.**
- Bovin, L. F.; Rieneck, K.; Workman, C.; Nielsen, H.; Sørensen, S. F.; Skjødt, H.; Florescu, A.; Brunak, S. and Bendtzen K. (2004):** Blood cell gene expression profiling in rheumatoid arthritis Discriminative genes and effect of rheumatoid factor. **Immunol. Lett., 93: 217–226.**
- Braun, L.; Mead, J. E.; Panzica, M.; Mikumo, R.; Bell, G. J. and Fausto, N. (1988):** Transforming growth factor B mRNA increases during liver regeneration: a possible mechanism of growth regulation. **Proc. Natl. Acad. Sci., 85: 1539–1543.**

- Brazelton, T. R. and Morris, R. E. (1996):** Molecular mechanisms of action of new xenobiotic immunosuppressive drugs: tacrolimus (FK506), sirolimus (rapamycin), mycophenolate mofetil and leflunomide. **Curr. Opin. Immunol., 8: 710–720.**
- Breedveld, F.C. (2001):** Is there a place for leflunomide in the treatment of rheumatoid arthritis? **Lancet, 358(9289): 1198-1200.**
- Brent, R. I. (2001):** Teratogen update: Reproductive risks of leflunomide (Arava); A pyrimidine synthesis inhibitor: Counseling women taking leflunomide before or during pregnancy and men taking leflunomide who are contemplating fathering a child. **Teratology, 63: 106-112.**
- Bruyn, G. A.; Griep, E. N. and Korff, K. J. (1999):** Leflunomide for active rheumatoid arthritis. **Lancet, 353: 1883.**
- Camras, C. B. (1999):** Latanoprost may trigger the biosynthesis of endogenous prostaglandins in early postoperative pseudophakias. **Arch. Ophthalmol., 117: 1265-1266.**
- Cao, W. W.; Kao, P. N.; Aoki, Y.; Xu, J. C.; Shorthouse, R. A. and Morris, R. E. (1996):** A novel mechanism of action of the immunomodulatory drug, leflunomide: Augmentation of the immunosuppressive cytokine, TGF-beta 1, and suppression of the immunostimulatory cytokine, IL-2. **Transplant. Proc., 28: 3079–3080.**
- Cao, W. W.; Kao, P. N.; Chao, A.; Gardner, P.; Ng, J. and Morris, R. (1995):** Mechanism of the anti-proliferative action of leflunomide. **J. Heart Lung Trans., 14: 1016–1030.**

- Capaldi, R. A.; Marusich, M. F. and Taanman, J. -W. (1995):** Mammalian cytochrome-c oxidase: characterization of enzyme and immunological detection of subunits in tissue extracts and whole cells. **Methods Enzymol.**, **260**: 117-133.
- Casanova, S. C.; Romá, S. E.; Pelufo, P. A. and Poveda, A. J. L. (2005):** Leflunomide: assessing teratogenic risk during the first trimester of pregnancy. **Farm. Hosp.**, **29(4)**: 265-268.
- Chambers, C. D.; Johnson, D. L.; Macaraeg, G. R. and Jones, K. L. (2004):** Pregnancy outcome following early gestational exposure to leflunomide: the OTIS Rheumatoid Arthritis in Pregnancy Study [abstract]. **Pharmacoepidemiol. Drug Safety**, **13**: S252.
- Chen, E. (1993):** Inhibition of cytochrome oxidase and blue-light damage in rat retina. **Graefe's Arch. Clin. Exp. Ophthalmol.**, **231**: 416-423.
- Chen, E.; Söderberg, P. G. and Lindström, B. (1989):** Activity distribution of cytochrome oxidase in the rat retina - a quantitative histochemical study. **Acta. Ophthalmol. (Copenh)**, **67**: 645-651.
- Chesne, C.; Guyomard, C.; Fautrel, A.; Poullain, M. G.; Fremond, B.; Dejong, H. and Guillouzo, A. (1993):** Viability and function in primary culture of adult hepatocytes from various animal species and human-beings after cryopreservation. **Hepatology**, **18**: 406-414.

- Chesne, C.; Guyomard, C.; Grislain, L.; Clerc, C.; Fautrel, A. and Guillouzo, A. (1991):** Use of cryopreserved animal and human hepatocytes for cytotoxicity studies. **Toxicol. In Vitro**, 5: 479-482.
- Cherwinski, H. M.; Cohn, R. G.; Cheung, P.; Webster, D. J.; Xu, Y. Z.; Caulfield, J. P.; Young, J. M.; Nakano, G. and Ransom, J. T. (1995):** The immunosuppressant leflunomide inhibits lymphocyte proliferation by inhibiting pyrimidine biosynthesis. **J. Pharmacol. Exp. Ther.**, 275: 1043–1049.
- Clark, D. (2005):** Molecular biology. **Elsevier Academic Press, London: 802.**
- Cohen, S. B. and Iqbal, I. (2003):** Leflunomide. **Int. J. Clin. Pract.**, 57(2): 115-120.
- Cohen, J.; Jorgensen, C. and Sany, J. (2004):** Leflunomide-induced aseptic meningitis. **Joint Bone Spine**, 71(3): 243-245.
- Collier, G. and Flood-Page, P. (2005):** A case of acute pneumonitis associated with leflunomide treatment. **Respir. Med. Extra**, 1(3): 35-37.
- Combe B. (2006):** Leflunomide combined with conventional disease-modifying antirheumatic drugs or biologics in patients with rheumatoid arthritis. **Joint Bone Spine**, 73: 587–590.
- Costello, L. C. and Franklin, R. B. (2006):** Tumor cell metabolism: the marriage of molecular genetics and proteomics with cellular intermediary metabolism; proceed with caution! **Mol. Cancer**, 59: 1-5.

- Culling, C. F. A. (1974):** Handbook of histopathological and histochemical techniques. **Butterworths, London.**
- Czaja, M.; Weiner, F.; Flanders, K.; Giambrone, M.; Wind, R.; Biempica, L. and Zern, M. (1989):** In vitro and in vivo association of transforming growth factor β 1 with hepatic fibrosis. **J. Cell. Biol., 108: 2477–2482.**
- Dailey and Dailey (1996):** Human Protoporphyrinogen oxidase: expression, purification and characterization of the cloned enzyme. **Protein Sci., 5(1): 98-105.**
- De Santis, M.; Straface, G.; Cavaliere, A.; Carducci, B. and Caruso, A. (2005):** Paternal and maternal exposure to leflunomide: pregnancy and neonatal outcome. **Ann. Rheum. Dis., 64:1096-1097.**
- Dimitrijevic, M. and Bartlett, R. R. (1996):** Leflunomide, a novel immunomodulating drug, inhibits homotypic adhesion of mononuclear cells in rheumatoid arthritis. **Transplant. Proc., 28: 3086–3087.**
- El- Balshy, R. M. (1991):** Effect of caffeine on the early developmental stages of the mouse. **Ph.D. Thesis, Fac. Sci., Benha univ., 208pp.**
- El-Banhawy, M. A. and Riad, N. A. (1972):** Influence of development, aging and fasting on the histochemical localization of proteins in the liver cells of guinea pigs. **Proc. Zool. Soc. (ARE), 4: 257-266.**

- Elder, R. T.; Xu, X.; Williams, J. W.; Gong, H.; Finnegan, A. and Chong, A. S. (1997):** The immunosuppressive metabolite of leflunomide, A77-1726, affects murine T cells through two biochemical mechanisms. **J. Immunol.**, **159**: 22–27.
- El Desoky, E. S. (2001):** Pharmacotherapy of rheumatoid arthritis: an overview. **Curr. Ther. Res.**, **62(2)**: 92-112.
- Elkayam, O.; Yaron, I.; Shirazi, I.; Judovitch, R.; Caspi, D. and Yaron, M. (2003):** Active leflunomide metabolite inhibits interleukin 1b, tumour necrosis factor a, nitric oxide, and metalloproteinase-3 production in activated human synovial tissue cultures. **Ann. Rheum. Dis.**, **62**: 440–443.
- Ezziane, Z. (2006):** Applications of artificial intelligence in bioinformatics: A review. **Expert. Systems with Applications**, **30**: 2–10.
- Fairbanks, L. D.; Bofill, M.; Ruckemann, K. and Simmonds, H. A. (1995):** Importance of ribonucleotide availability to proliferating T-lymphocytes from healthy humans. Disproportionate expansion of pyrimidine pools and contrasting effects of de novo synthesis inhibitors. **J. Biol. Chem.**, **270**: 29682–29689.
- Finn, C. A. and McLaren, H. (1967):** A study of the early stages of implantation in mice. **J. Reprod. Fertil.**, **13**: 259- 267.
- Forsdyke, D. R. (1995a):** Relative roles of primary sequence and (G+C)% in determining the hierarchy of frequencies of complementary trinucleotide pairs in DNAs of different species. **J. Mol. Evol.**, **41**: 573-581.

- Forsdyke, D. R. (1995b):** Reciprocal relationship between stem-loop potential and substitution density in retroviral quasispecies under positive Darwinian selection. **J. Mol. Evol., 41: 1022-1037.**
- Forsdyke, D. R. (1996):** Stem-loop potential in MHC genes: a new way of evaluating positive Darwinian selection? **Immunogenetics, 43: 182-189.**
- Forsdyke, D. R. (1998):** An alternative way of thinking about stem-loops in DNA: A case study of the human G0S2 gene. **J. Theor. Biol., 192: 489-504.**
- Fox, R. I.; Herrmann, M. L.; Frangou, C. G.; Wahl, G. M.; Morris, R. E.; Strand, V. and Kirschbaum, B. J. (1999):** Mechanism of Action for Leflunomide in Rheumatoid Arthritis. **Clin. Immunol., 93(3): 198-208.**
- Fresco, J. R.; Alberts, B. M. and Dotys, P. (1960):** Some molecular details of the secondary structure of ribonucleic acid. **Nature, 188: 98-101.**
- Fresco, J. R.; Klotz, I., C. and Richardsa, E. G. (1963):** New spectroscopic approach to the determination of helical secondary structure in ribonucleic acids. **Cold Spring Harbor Symp. Quant. Biol., 28: 83.**
- Frohberg, H. (1977):** An introduction to research in teratology in "Methods in prenatal toxicology". **Georg Thieme publishers, Stuttgart.**

- Fukushima, R.; Kanamori, S.; Hirashiba, M.; Hishikawa, A.; Muranaka, R. I.; Kaneto, M. and Kitagawa, H. (2009a):** Inhibiting the teratogenicity of the immunosuppressant Leflunomide in mice by supplementation of exogenous uridine. **Toxicol Sci., 108: 419–426.**
- Fukushima, R.; Kanamori, S.; Hirashiba, M.; Hishikawa, A.; Muranaka, R.; Kaneto, M.; Nakamura, K. and Kato, I. (2007):** Teratogenicity study of the dihydroorotate-dehydrogenase inhibitor and protein tyrosine kinase inhibitor Leflunomide in mice. **Reprod. Toxicol., 24: 310–316.**
- Fukushima, R.; Kaneto, M. and Kitagawa, H. (2009b):** Microarray analysis of Leflunomide-induced limb malformations in CD-1 mice. **Reprod. Toxicol., 29 (1): 42-48.**
- Gabay, C. (2001):** Gene therapy: will it deliver for RA? **DDT, 6(7): 343-344.**
- Gacy, A. M.; Goellner, G.; Juranic, N.; Macura, S. and McMurray, C. T. (1995):** Trinucleotide repeats that expand in human disease form hairpin structures in vitro. **Cell, 81: 533-540.**
- Ghadially, F. N. (1982):** Ultrastructural pathology of the cell and matrix. **2nd ed. Butterworths, London, Boston, Sydney.**
- Gleich, J. and Frohberg, H. (1977):** General teratological techniques, In "Methods in prenatal toxicology". **Georg Thieme publishers Stuttgart.**

- Goëb, V.; Berthelot, J. M.; Joly, P.; Mejjad, O.; de Quatrebarbes, J.; Reynaud-Hautin, C.; Vittecoq, O. and Le Loët, X. (2005):** Leflunomide-induced subacute cutaneous lupus erythematosus. **Rheumatology**, **44(6): 823-824.**
- Goldenberg, M. M. (1999):** Leflunomide, a Novel Immunomodulator for the Treatment of Active Rheumatoid Arthritis. **Clin. Ther.**, **21(11): 1837- 1852.**
- Gottwald, U.; Davies, B.; Fritsch, M. and Habenicht, U. F. (2006):** New approaches for male fertility control: HE6 as an example of a putative target. **Mol. Cell. Endocrinol.**, **250: 49–57.**
- Graul, A. and Castaner, J. (1998):** Leflunomide. **Drugs Future**, **23: 827–837.**
- Greene, S.; Watanabe, K.; Braatz-Trulson, J. and Lou, L. (1995):** Inhibition of dihydroorotate dehydrogenase by the immunosuppressive agent leflunomide. **Biochem. Pharmacol.**, **50: 861–867.**
- Groebe, D. R. and Uhlenbeck, O. C. (1988):** Characterization of RNA hairpin loop stability. **Nucleic Acids Res.**, **16(24): 11725-11735.**
- Hamilton, L.; Vojnovic, I.; Bakhle, Y.; Warner, T. and Vane, J. (1996):** The anti-inflammatory drug leflunomide inhibits in vitro and in vivo the activity of COX-2 more potently than the induction of COX-2 or iNOS. **Proc. Br. Pharmacol. Soc.**, **18: C51.**

- Hancock, W. W.; Miyatake, T.; Koyamada, N.; Kut, J. P.; Soares, M.; Russell, M. E.; Bach, F. H. and Sayegh, M. H. (1997):** Effects of leflunomide and deoxyspergualin in the guinea pig3rat cardiac model of delayed xenograft rejection: Suppression of B cell and C–C chemokine responses but not induction of macrophage lectin. **Transplantation, 64: 696–704.**
- Haydar, A. A.; Hujairi, N.; Kirkham, B.; Hangartner, R. and Goldsmith, D. J. (2004):** Chronic overdose of leflunomide inducing interstitial nephritis. **Nephrol. Dial. Transplant., 19(5): 1334-1335.**
- Herrmann, M. L.; Schleyerbach, R. and Kirschbaum, B. J. (2000):** Leflunomide: an immunomodulatory drug for the treatment of rheumatoid arthritis and other autoimmune diseases. **Immunopharmacology, 47(2-3): 273-289.**
- Higgs, P. G. (1993):** RNA secondary structure: a comparison of real and randomb sequences. **J. Phys. I France, 3: 43-59.**
- Hocevar, A.; Rozman, B.; Praprotnik, S.; Lestan, B.; Erzen, D.; Petric, V. and Tomsic, M. (2006):** Leflunomide-associated tuberculosis? **Rheumatology, 45(2): 228-229.**
- Hugo, E. R.; Stewart, V. J.; Gast, R. J. and Byers, T. J. (1992):** Purification of amoeba mtDNA using the UNSET procedure. **In "protocols in protozoology" J. J. Lee & A. T. Soldo, eds. Soc. Protozoologists, Lawrence, KA., D7.1-D7.2.**

- Ionov, Y.; Peinado, M. A.; Malkhosyan, S.; Shibata, D. and Perucho, M. (1993):** "Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis". **Nature**, **363**: 558-561.
- Jakob, A.; Porstmann, R. and Rompel, R. (2006):** Skin ulceration after leflunomide treatment in two patients with rheumatoid arthritis. **J. Dtsch. Dermatol. Ges.**, **4(4)**: 324-327.
- Jankovic, V.; Samardzic, T.; Stosic-Grujicic, S.; Popadic, D. and Trajkovic, V. (2000):** Cell-Specific Inhibition of Inducible Nitric Oxide Synthase Activation by Leflunomide. **Cell. Immunol.**, **199 (2, 1)**: 73-80.
- Jeon, Y. J.; Han, S. H.; Yang, K. H. and Kaminski, N. E. (1997):** Induction of liver-associated transforming growth factor $\beta 1$ (TGF- $\beta 1$) mRNA expression by carbon tetrachloride leads to the inhibition of T helper 2 cell-associated lymphokines. **Toxicol. Appl. Pharmacol.**, **144**: 27–35.
- Jover, R. Ponsoda, X.; Castell, J. V. and Gomezlechón, M. J. (1992):** Evaluation of the cytotoxicity of 10 chemicals on human cultured-hepatocytes-predictability of human toxicity and comparison with rodent cell-culture systems. **Toxicol. In Vitro**, **6**: 47-52.
- Ju, D. W.; Zheng, Q. Y.; Wang, H. B. and Fang, J. (1994):** Leflunomide inhibits PAF induced DNA synthesis in rabbit synovial cells and PAF production from rat peritoneal macrophages. **Yao Xue Xue Bao.**, **29(2)**: 90-94.

- Kadenbach, B.; Jarausch, J.; Hartmann, R. and Merle, P. (1983):** Separation of mammalian cytochrome c oxidase into 13 polypeptides by a sodium dodecyl sulfate-gel electrophoretic procedure. **Analyt. Biochem.**, **129**: 517–521.
- Kadenbach, B.; Stroh, A.; Becker, A.; Eckerskorn, C.; Lottspeich, F. (1990):** Tissue- and species-specific expression of cytochrome c oxidase isozymes in vertebrates. **Biochim. Biophys. Acta.**, **1015**: 368–372.
- Kadenbach, B.; Hüttemann, M.; Arnold, S.; Lee, I. and Bender, E. (2000):** Mitochondrial energy metabolism is regulated via nuclear-coded subunits of cytochrome c oxidase. **Free Rad. Biol. Med.**, **29**: 211–221.
- Kadenbach, B.; Stroh, A.; Hüther, F.-J.; Reimann, A. and Steverding, D. (1991):** Evolutionary Aspects of Cytochrome c Oxidase. **J. Bioenergetics and Biomembranes**, **23**(2): 321-334.
- Kamath, S. and Hassell, A. B. (2003):** Management of inflammatory arthritis in the older person. **Reviews in Clinical Gerontology**, **13**: 283–296.
- Kawato, S.; Sigel, E.; Carafoli, E. and Cherry, R. J. (1981):** Rotation of cytochrome oxidase in phospholipid vesicles: Investigations of interactions between cytochrome oxidases and between cytochrome oxidase and cytochrome *bc*₁ complex. **J. boil. chem.**, **256**(14): 7518-7527.

- Kemp, E.; Nielsen, H.; Petersen, L. J.; Gam, A. N.; Dahlager, J.; Horn, T.; Larsen, S. and Olsen, S. (2001):** Newer immunomodulating drugs in rheumatoid arthritis may precipitate glomerulonephritis. **Clin. Nephrol.**, 55(1): 87-88.
- Kehrl, J.; Wakefield, L.; Roberts, A.; Jakowlew, S.; Alvarez- Mon, M.; Derynck, R.; Sporn, M. and Fauci, A. (1986):** Production of transforming growth factor β by human T lymphocytes and its potential role in the regulation of T cell growth. **J. Exp. Med.**, 163: 1037–1050.
- Kehrl, J. H.; Thevenin, C.; Rieckmann, P. and Fauci, A. S. (1991):** Transforming growth factor β lymphocyte Ig production by inhibiting synthesis and the switch from the membrane form to the secreted form of Ig mRNA. **J. Immunol.**, 146: 4016–4023.
- Kent, E. F.; Crawford, J.; Choen, H. J. and Buckley, R. H. (1990):** Development of multiple monoclonal serum immunoglobulins (multiclonal gammopathy) following both HLA-identical unfractionated and T cell-depleted haploidentical bone marrow transplantation in severe combined immunodeficiency. **J. Clin. Immunol.**, 10: 106–113.
- Kerr, O. A.; Murray, C. S. and Tidman, M. J. (2004):** Subacute cutaneous lupus erythematosus associated with leflunomide. **Clin. Exp. Dermatol.**, 29(3): 319-320.

- Kessel, A. and Toubi, E. (2002):** Leflunomide in systemic lupus erythematosus. **Harefuah., 141(4): 355-357.**
- Konstantinov, A. A. (1998):** Cytochrome c oxidase as a protonpumping peroxidase: reaction cycle and electrogenic mechanism. **J Bioenerg. Biomembr., 30: 121-130.**
- Kuo, L. C.; Zambidis, I. and Caron, C. (1989):** Triggering of allostery in an enzyme by a point mutation: ornithine transcarbamoylase. **Science, 245: 522-524.**
- Lawrence, J. N. and Benford, D. J. (1990):** Toxicity of paracetamol and cyclophosphamide in monolayer-cultures of rat and human hepatocytes. **Toxicol. In Vitro, 4: 443-448.**
- Lawwill, T. (1982):** Three major pathologic processes caused by light in the primate retina: a search for mechanisms. **Trans. Am. Ophthalmol. Soc., 80: 517-579.**
- Le, S.-Y. and Maizel, J. V. (1989):** A method for assessing the statistical significance of RNA folding. **J. Theor. Biol., 138: 495-510.**
- Leeder, S. J.; Lu, X.; Timsit, Y. and Gaedigk, A. (1998):** Nonmono-oxygenase cytochromes P450 as potential autoantigens in anticonvulsant hypersensitivity reactions. **Pharmacogenetics, 8: 211–225.**
- Leger, D. Y; Liagre, B. and Beneytout, J. L. (2006):** Low dose leflunomide activates PI3K/Akt signalling in erythroleukemia cells and reduces apoptosis induced by anticancer agents. **Apoptosis, 11(10):1747-1760.**

- Legras, A.; Bergemer-Fouquet, A. and Jonville-Bera, A. (2002):** Fatal hepatitis with leflunomide and itraconazole. **Am. J. Med., 113(4): 352-353.**
- Lenka N, Vijayasathya C, Mullick J, Avadhani NG: (1998)** Structural organization and transcription regulation of nuclear genes encoding the mammalian cytochrome c oxidase complex. **Prog. Nucleic Acid Res. Mol. Biol., 61:309–344.**
- Li, A. P. (2002):** A review of the common properties of drugs with idiosyncratic hepatotoxicity and the “multiple determinant hypothesis” for the manifestation of idiosyncratic drug toxicity. **Chemico-Biol. Interactions, 142: 7-23.**
- Li, W. D. and Lin, Z. B. (2002):** Effects of leflunomide and its active metabolite on the production and mRNA expression of TNF- α in peritoneal macrophages and synovial cells with adjuvant arthritis in rats. **Yao Xue Xue Bao., 37(10): 767-770.**
- Li, E. K.; Tam, L.-S. and Tomlinson, B. (2004):** Leflunomide in the treatment of rheumatoid arthritis. **Clin. Ther., 26(4): 447-459.**
- Lin, Y.; Ji, P.; Xia, G.; Vandeputte, M. and Waer, M. (1998):** Blockade of induced xenoantigen expression prevents rejection after retransplantation of accommodated hamster-to-rat heart xenografts. **Transplantation, 65: 340–345.**

- Linder, D.; Freund, R.; Kadenbach, B. (1995):** Species-specific expression of cytochrome c oxidase isozymes. **Comp. Biochem. Physiol., 112B:461–469.**
- Litinsky, I.; Paran, D.; Levartovsky, D.; Wigler, I.; Kaufman, I.; Yaron, I.; Yaron, M.; Caspi, D. and Elkayam O. (2006):** The effects of leflunomide on clinical parameters and serum levels of IL-6, IL-10, MMP-1 and MMP-3 in patients with resistant rheumatoid arthritis. **Cytokine, 33(2): 106-110.**
- Lowry, O. H. (1975):** Energy metabolism in brain and its control. **In: D.H. Ingvar and N.A. Lassen (Eds.), Brain Work. Alfred Benzon Symposium VIII. Academic Press, New York.**
- Mangge, H.; Gratze, P. and Hermann, S. (2001):** Serum levels of matrixmetalloproteinases MMP1 (collagenase) and MMP3 (stromelysin) before and after treatment with leflunamide in patients with rheumatoid arthritis. **Arthritis Res., 3(2): 89.**
- Manna S. K. and Aggarwal, B. B. (1999):** Immunosuppressive Leflunomide Metabolite (A77 1726) Blocks TNF-Dependent Nuclear Factor-kB Activation and Gene Expression. **J. Immunol., 162: 2095–2102.**
- Manna, S. K.; Mukhopadhyay, A. and Aggarwal, B. B. (2000):** Leflunomide suppresses TNF-induced cellular responses: effects on NF-kappa B, activator protein-1, c-Jun N-terminal protein kinase, and apoptosis. **J. Immunol., 165: 5962–5969.**

- Marchesoni, A.; Arreghini, M.; Panni, B.; Battafarano, N. and Uziel, L. (2003):** Life-threatening reversible bone marrow toxicity in a rheumatoid arthritis patient switched from leflunomide to infliximab. **Rheumatology**, 42: 193-194.
- Martin, N.; Innes, J. A.; Lambert, C. M.; Turnbull, C. M. and Wallace, W. A. (2007):** Hypersensitivity pneumonitis associated with leflunomide therapy. **J. Rheumatol.**, 34(9): 1934-1937.
- Martinez-Taboada, V. M.; Rodriguez-Valverde, V.; Gonzalez-Vilchez, F. and Armijo, J. A. (2004):** Pulmonary hypertension in a patient with rheumatoid arthritis treated with leflunomide. **Rheumatology**, 43(11): 1451-1453.
- Mazia, D.; Brewer, P. and Alfert, M. (1953):** The cytochemical staining and measurement of protein with mercuric bromophenol blue. **Biol. Bull.**, 104: 57-67.
- McChesney, L. P.; Xiao, P.; Sankary, H. N.; Foster, P. F.; Sharma, S.; Haklin, M. and Williams, J. W. (1994):** An evaluation of leflunomide in the canine renal transplantation model. **Transplantation**, 57: 1717-1722.
- McClain, R. M. and Becker, B. A. (1975):** Teratogenicity, fetal toxicity and placental transfer of lead nitrate in rats. **Toxicol. App. Pharmacol.**, 31: 72-82.
- McCoy, C. M. (2002):** Leflunomide-associated skin ulceration. **Ann. Pharmacother.**, 36(6): 1009-1011.

- Melvin, R. G.; Katewa, S. D. and Ballard, J. W. O. (2008):** A candidate complex approach to study functional mitochondrial DNA changes: sequence variation and quaternary structure modeling of drosophila simulans Cytochrome c Oxidase. **J. Mol. Evol.**, **66**:232–242.
- Meyer, W.; Bauer, M. and Pratje, E. (1997):** A mutation in cytochrome oxidase subunit 2 restores respiration of the mutant pet ts1402. **Curr. Genet.**, **31**: 401–407.
- Miljkovic, D. J.; Samardzic, T.; Mostarica Stojkovic, M.; Stosic-Grujicic, S.; Popadic, D.; and Trajkovic, V. (2001):** Leflunomide inhibits activation of inducible nitric oxide synthase in rat astrocytes. **Brain Res.**, **889** (1-2): 331-338.
- Min Jou, W. and Fiers, W. (1976):** Studies on the bacteriophage MS2. XXXIII: Comparison of the nucleotide sequences in related bacteriophage RNAs. **J. Mol. Biol.**, **106**: 1047-1060.
- Mizushima, Y. Amano, Y. Kitagawa, H. and Ogata, K. (1999):** Oral Administration of Leflunomide (HWA486) Results in Prominent Suppression of Immunoglobulin E Formation in a Rat Type 1 Allergy Model. **JPET**, **288**: 849–857.
- Mobley, J. L. (2004):** Is rheumatoid arthritis a consequence of natural selection for enhanced tuberculosis resistance? **Med. Hypotheses**, **62**(5): 839-843.

- Murchie, A. I. H.; Bowater, R.; Aboul-Ela, F. and Lilley, D. M. J. (1992):** Helix opening transitions in supercoiled DNA. **Biochem. Biophys. Acta., 1131:1-15.**
- Nelson, S. D. (1990):** Molecular mechanisms of the hepatotoxicity caused by acetaminophen. **Semin. Liver Dis., 10: 267-278.**
- Nelson, S. D. (2001):** Molecular Mechanisms of Adverse Drug Reactions. **Curr. Ther. Res., 62 (12): 885-899.**
- Nie, F. and Wong-Riley, M. T. (1996):** Mitochondrial and nuclear encoded subunits of cytochrome oxidase in neurons: differences in compartmental distribution, correlation with enzyme activity, and regulation by neural activity. **J. Comp. Neurol., 373: 139-155.**
- Nielsen, D. A.; Novoradovsky, A. and Goldman, D. (1995):** SSCP primer design based on single-strand DNA structure predicted by a DNA folding program. **Nucleic Acids Res., 23: 2287-2291.**
- Omoto, C. K. and Lurquin, P. F. (2004):** Genes and DNA: A beginner's guide to genetics and its applications. **Columbia Univ. Press, New York, pp239.**
- Orita, M.; Iwahana, H.; Kanazawa, H.; Hayashi, K. and Sekiya, T. (1989):** Detection of polymorphisms of human DNA by gel electrophoresis as single strand conformation polymorphisms. **Proc. Natl. Acad. Sci. USA, 86: 2766-2770.**

- Østensen, M. (2006):** Antirheumatic therapy and reproduction. The influence on fertility, pregnancy and breast feeding. **Z. Rheumatol.**, 65(3): 217-220, 222-224.
- Østensen, M.; Von Eisebeck, M. and Villiger, P. M. (2007):** Therapy with immunosuppressive drugs and biological agents and use of contraception in patients with rheumatic disease. **J. Rheumatol.**, 34(6): 1266-1269.
- Otter, M. W., Leod, K. J. and Rubin, C.T. (1998):** Effects of electromagnetic fields in experimental fracture repair. **Clin. Orthopedics and Related Res.**, 355S: 50-104.
- Panico, A.; Cardile, V.; Gentile, B.; Garufi, F.; Fama', P.; Bonfiglio, G. and Ronsisvalle, G. (2003):** Effects of leflunomide on human cartilage. **Farmaco**, 58(9): 983-987.
- Pap, T.; Cinski, A.; Baier, A.; Gay, S. and Meinecke, I. (2003):** Modulation of pathways regulating both the invasiveness and apoptosis in rheumatoid arthritis synovial fibroblasts. **Joint Bone Spine**, 70: 477–479.
- Park, B. K.; Pirmohamed, M. and Kitteringham, N. R. (1995):** The role of Cytochrome P450 enzymes in hepatic and extrahepatic human drug toxicity. **Pharmac. Ther.**, 68(3): 385-424.
- Park, B. K.; Pirmohamed, M. and Kitteringham, N. R. (1998):** Role of drug disposition in drug hypersensitivity: a chemical, molecular and clinical perspective. **Chem. Res. Toxicol.**, 9: 969–988.

- Park, B. K.; Kitteringham, N. R. and Pirmohamed, M. (2000):** Advances in molecular toxicology—towards understanding idiosyncratic drug toxicity. **Toxicology**, **153**: 39–60.
- Park, B. K.; Tingle, M. D.; Grabowski, P. S.; Coleman, J. W. and Kitteringham, N. R. (1987):** Drug-protein conjugates—XI. Disposition and immunogenicity of dinitrofluorobenzene, a model compound for the investigation of drugs as haptens, **Biochem. Pharmacol.**, **36**: 591–599.
- Pautter, E. L.; Morita, M. and Beezley, D. (1989):** Reversible and irreversible blue light damage to the isolated, mammalian pigment epithelium. In inherited and environmentally induced retinal degenerations (**M. M. LaVail, J. G. Hollyfield, and R. E. Anderson, eds**). New York: Liss, 555-567.
- Pautter, E. L.; Morita, M. and Beezley, D. (1990):** Hemoprotein(s) mediate blue light damage in the retinal pigment epithelium. **Photochem. Photobiol.**, **51**: 599-605.
- Perdriger, A.; Mariette, X.; Kuntz, J. L.; Brocq, O.; Kara-Terki, R.; Loet, X. L.; Cantagrel, A.; Pavy, S.; Deslandre, C. J.; Debiais, F. and Combe, B. (2006):** Safety of infliximab used in combination with leflunomide or azathioprine in daily clinical practice. **J. Rheumatol.**, **33**(5): 865-869.
- Pereira, C.; Fallon, P. G.; Cornette, J.; Capron, A.; Doenhoff, M. J. and Pierce, R. J. (1998):** Alterations in cytochrome-c oxidase expression between praziquantel-resistant and susceptible strains of *Schistosoma mansoni*. **Parasitology**, **117**: 63-73.

- Pichler, W.J. (2002):** Pharmacological interaction of drugs with antigen-specific immune receptors: **Allergy Clin. Immunol., 2: 301–305.**
- Pinto, P. and Dougados, M. (2006):** Leflunomide in clinical practice. **Acta. Reumatol. Port., 31(3): 215-224.**
- Pirmohamed, M.; Kitteringham, N. R. and Park, B. K. (1994):** The role of active metabolites in drug toxicity. **Drug Saf., 11: 114-144.**
- Ponsoda, X.; Jover, R.; Gomezlechón, M. J.; Fabra, R.; Trullenque, R. and Caste J. V. (1991):** Intracellular glutathione in human hepatocytes incubated with S-adenosyl-L-methionine and GSH-depleting drugs. **Toxicology, 70: 293-302.**
- Prakist, A. and Jarvis, B. (1999):** Leflunomide. A review of its use in active rheumatoid arthritis. **Drugs, 58: 1137-1164.**
- Qiu, Y.; Benet, L. Z. and Burlingame, A. L. (1998):** Identification of the hepatic protein targets of reactive metabolites of acetaminophen in vivo in mice using two-dimensional gel electrophoresis and mass spectrometry. **J. Biol. Chem., 273: 17940–17953.**
- Rapp, L. M.; Tolman, B. L. and Dhindsa, H. S. (1990):** Separate mechanisms for retinal damage by ultraviolet-A and mid-visible light. **Invest. Ophthalmol. Vis. Sci., 31: 1186-1190.**
- Raucy, J. L.; Lasker, J. M.; Lieber, C. S. and Black, M. (1989):** Acetaminophen activation by human liver cytochromes 'P-450IIE1 and P-450IA2. **Arch. Biochem. Biophys., 271: 270-283.**

- Rozman, B.; Praprotnik, S.; Logar, D.; Tomsic, M.; Hojnik, M.; Kos-Golja, M.; Accetto, R. and Dolenc, P. (2002):** Leflunomide and hypertension. **Ann. Rheum. Dis., 61(6): 567-569.**
- Salser, W. (1977):** Globin mRNA sequences: analysis of base pairing and evolutionary implications. **Cold Spring Harbor Symp. Quant. Biol., 42: 985-1002.**
- Sanofi-aventis, K. K. (2003):** Leflunomide Summary Basis for Approval submitted to Japan Ministry of Health, Labor and Welfare (Japanese). **Tokyo, Japan.**
- Sato, K.; Yamaguchi, L. I.; Miyamoto, H. and Kinouchi, Y. (1992):** Growth of human cultured cells exposed to a non-homogenous static magnetic field generated by Sm – Co magnets. **Biochem. Biophys. Acta., 1136(3): 231-238.**
- Savage, R. L.; Highton, J.; Boyd, I. W. and Chapman, P. (2006):** Pneumonitis associated with leflunomide: **a profile of New Zealand and Australian reports. Intern Med J., 36(3):162-169.**
- Sawyer, S. A.; Parsch, J.; Zhang, Z. and Hartl, D. L. (2007):** "Prevalence of positive selection among nearly neutral amino acid replacements in *Drosophila*". **Proc. Natl. Acad. Sci. U.S.A., 104 (16): 6504-6510.**
- Scarpulla, R. C. (2002):** Transcriptional activators and coactivators in the nuclear control of mitochondrial function in mammalian cells. **Gene, 286: 81-89.**

- Scarpulla, R.C. (2006):** Nuclear control of respiratory gene expression in mammalian cells. **J. Cell Biochem.**, 97: 673–683.
- Schardein, I. J. (1977):** Drugs as teratogens. **CRC press, Inc. ohio, U.S.A.**
- Sevilla-Mantilla, C.; Ortega, L.; Agúndez, J. A. G.; Fernández-Gutiérrez, B.; Ladero, J. M.; and Díaz-Rubio, M. (2004):** Leflunomide-induced acute hepatitis. **Dig. Liver Dis.**, 36(1): 82-84.
- Shastri, V.; Betkerur, J.; Kushalappa, P. A.; Savita, T. G. and Parthasarathi, G. (2006):** Severe cutaneous adverse drug reaction to leflunomide: a report of five cases. **Indian J. Dermatol. Venereol. Leprol.**, 72(4): 286-289.
- Sheehan, D. C. and Hrapchak, B. R. (1980):** Theory and Practice of Histotechnology. 2nd Ed, CV Mosby, St. Louis, pp. 150.
- Shentona, J. M.; Chena, J. and Uetrecht, J. P. (2004):** Animal models of idiosyncratic drug reactions. **Chemico-Biol. Interactions**, 150: 53–70.
- Shull, M. M.; Ormsby, I.; Kier, A. B.; Pawlowski, S.; Diebold, R. J.; Yin, M.; Allen, R.; Sidman, C.; Proetzel, G.; Calvin, D.; Annunziata, N. and Doetschman, T. (1992):** Targeted disruption of the mouse transforming growth factor beta-1 gene results in a multifocal inflammatory disease. **Nature**, 359: 693–699.

- Sillard, R.; Jörnvall, H. and Mutt, V. (1993):** Characterization of porcine intestinal cytochrome c oxidase subunit VIIc, purified by affinity chromatography. **Biochem. Biophys. Res. Commun.**, 195(2): 746-750.
- Silva, H. T. Jr.; Cao, W.; Shorthouse, R. A. and Morris, R. E. (1996):** Mechanism of action of leflunomide: In vivo uridine administration reverses its inhibition of lymphocyte proliferation. **Transplant. Proc.**, 28: 3082–3084.
- Simon, L. S. (2004):** The treatment of rheumatoid arthritis. **Best Pract. Res. Clin. Rheumatol.**, 18(4): 507-538.
- Sivaprasada, K.; Sambasiva, K. R. and Roma, K.V. (1983):** Effect of parathion on tissue ionic changes in fish *Channa punctatus*. **Geobios (JODHPUR)**, 10 (2): 60-62.
- Smolen, J. S.; Kalden, J. R.; Scott, D. L.; Rozman, B.; Kvien, T. K.; Larsen, A.; Loew-Friedrich, I.; Oed, C. and Rosenberg, R. (1999):** Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group. **Lancet**, 353(9149): 259-266.
- Snell, G. D. (1956):** Biology of the laboratory mouse. 5th ed. **The Blakiston Co. Philadelphia** pp: 1-88.
- Soliotis, F.; Glover, M. and Jawad, A. S. (2002):** Severe skin reaction after leflunomide and etanercept in a patient with rheumatoid arthritis. **Ann. Rheum. Dis.**, 61(9): 850-851.

- Spiridonov, N. A.; Wong, L.; Zervas, P. M.; Starost, M. F.; Pack, S. D.; Paweletz, C. P. and Johnson, G. R. (2005):** Identification and characterization of SSTK, a serine/threonine protein kinase essential for male fertility. **Mol. Cell Biol.**, 25: 4250–4261.
- Spodnik, J. H.; Wozniak, M.; Budzko, D.; Teranishi, M.; Karbowski, M.; Nishizawa, Y.; Usukura, J. and Wakabayashi, T. (2002):** Mechanism of leflunomide-induced proliferation of mitochondria in mammalian cells. **Mitochondrion**, 2(3): 163-179.
- Sueoka, N. (1961):** Correlation between Base Composition of Deoxyribonucleic Acid and Amino Acid Composition of Protein. **Proc. Natl. Acad. Sci. USA**, 47: 1141-1149.
- Suzuki, S.; Sakamoto, S.; Kudo, H.; Sassa, S.; Sugiura, Y.; Kuwa, K.; Kasahara, N.; Mori, T. and Nagasawa, H. (1993):** Effects of danazol on endometrial DNA synthesis in rats. **Steroids**, 58(11): 551-553.
- Tarner, I. H.; Neumann, E.; Gay, S. Fathman, C. G. and Müller-Ladner U. (2006):** Developing the concept of adoptive cellular gene therapy of rheumatoid arthritis. **Autoimmunity Rev.**, 5: 148–152.
- Terada, M. and Nishimura, H. (1975):** Mitigation of caffeine- induced teratogenicity in mice by prior chronic caffeine ingestion. **Teratology**, 12 (1): 79-82.

- Thummel, K. E.; Lee, C. A.; Kunze, K. L.; Nelson, S. D. and Slattery, J. T. (1993):** Oxidation of acetaminophen to N-acetyl-p-aminobenzoquinone imine by human CYP3A4. **Biochem. Pharmacol.**, 45: 1563-1569.
- Vallbracht, I. I.; Popper, H. H.; Rieber, J.; Nowak, F.; Gallenberger, S.; Piper, B. and Helmke, K. (2005):** Lethal pneumonitis under leflunomide therapy. **Rheumatology**, 44(12): 1580-1581.
- Van der Heijden, J. W.; Dijkmans, B. A.; Scheper, R. J. and Jansen, G. (2007):** Drug Insight: resistance to methotrexate and other disease-modifying antirheumatic drugs--from bench to bedside. **Nat. Clin. Pract. Rheumatol.**, 3(1): 26-34.
- Vergne-Salle, P.; Léger, D. Y.; Bertin, P.; Trèves, R.; Beneytout, J. and Liagre, B. (2005):** Effects of the active metabolite of leflunomide, A77 1726, on cytokine release and the MAPK signalling pathway in human rheumatoid arthritis synoviocytes. **Cytokine**, 31: 335-348.
- Vuolteenaho, K.; Kujala, P.; Moilanen, T. and Moilanen, E. (2005):** Aurothiomalate and hydroxychloroquine inhibit nitric oxide production in chondrocytes and in human osteoarthritic cartilage. **Scand. J. Rheumatol.**, 34(6): 475-479.
- Waer, M. (1998):** Leflunomide, malononitriloamides, and transplantation immunology. **Transplant. Rev.**, 12(3): 156-164.

- Walter, J. B. and Israel, M. S. (1987):** General pathology. 6th ed. Livingstone Churchill Edinburgh, London, New York, pp. 57-67& 897-899.
- Wardwell, N. R. Jr.; Miller, R. and Ware, L. B. (2006):** Pulmonary alveolar proteinosis associated with a disease-modifying antirheumatoid arthritis drug. **Respirology**, 11(5): 663-665.
- Waterman, M. S. (1978):** Secondary structure of single-stranded nucleic Acids. **Advances in Math.**, 1: 167-212.
- Weber, S. and Harnisch, L. (1997):** Use of a population pharmacokinetic model to predict clinical outcome of leflunomide, a new DMARD, in the treatment of rheumatoid arthritis. **J. Rheum.**
- Westhead, D. R.; Parish, J. H. and Twyman, R. M. (2002):** Bioinformatics. Oxford, Bios.
- Williamson, R. A.; Yea, C. M.; Robson, P. A.; Curnock, A. P.; Gadher, S.; Hambleton, A. B.; Woodward, K.; Bruneau, J. M.; Hambleton, P. and Moss, D. *et al.*, (1995):** Dihydroorotate dehydrogenase is a high affinity binding protein for A77-1726 and mediator of a range of biological effects of the immunomodulatory compound. **J. Biol. Chem.**, 270: 22467–22472.
- Wisniewski, H.G. and Vilček, J. (2004):** Cytokine-induced gene expression at the crossroads of innate immunity, inflammation and fertility: TSG-6 and PTX3/TSG-14. **Cytokine & Growth Factor Reviews**, 15: 129–146.

- Wong-Riley, M. T. T. (1989):** Cytochrome oxidase: an endogenous metabolic marker for neuronal activity. **Trends Neurosci.**, **12: 94–101.**
- Wong-Riley, M. T. T.; Liang, H. L. and Ongwijitwat, S. (2008):** Activity-dependent bigenomic transcriptional regulation of Cytochrome c Oxidase in neurons. **S. M. Dudek (ed.), Transcriptional Regulation by Neuronal Activity**, pp. 209- 228.
- Wong-Riley, M. T. T.; Nie, F.; Hevner, R. F. and Liu, S. (1998):** Brain cytochrome oxidase: Functional significance and bigenomic regulation in the CNS. **In: F. Gonzalez-Lima (Ed.), Cytochrome oxidase in neuronal metabolism and Alzheimer's Disease. Plenum Press, New York, PP 1–53.**
- Wu, J. Y.; Ribar, T. J.; Cummings, D. E.; Burton, K. A.; McKnight, G. S. and Means, A. R. (2000):** Spermiogenesis and exchange of basic nuclear proteins are impaired in male germ cells lacking Camk4. **Nat. Genet.**, **25: 448–452.**
- Xu, X., Williams, J. W.; Bremer, E. G.; Finnegan, A. and Chong, A. S. (1995):** Inhibition of protein tyrosine phosphorylation in T cells by a novel immunosuppressive agent, leflunomide. **J. Biol. Chem.**, **270: 12398–12403.**
- Yao, H. W.; Li, J.; Chen, J. Q. and Xu, S. Y. (2004):** A 771726, the active metabolite of leflunomide, inhibits TNF-alpha and IL-1 from Kupffer cells. **Inflammation**, **28(2): 97-103.**

- Yee, N. S.; Gong, W.; Huang, Y.; Lorent, K. and Dolan, A. C. (2007):** Mutation of RNA Pol III subunit *rpc2/polr3b* leads to deficiency of subunit *Rpc11* and disrupts zebrafish digestive development. **PLoS Biol.**, 5(11): 1371.
- Yeh, L. S.; Gregory, C. R.; Griffey, S. M.; Lecouteur, R. A. and Morris, R. E. (1996):** Effects of leflunomide and cyclosporine on myocutaneous allograft survival in the rat. **Transplantation**, 62: 861–863.
- Yocum, D. E. (1999): T Cells: Pathogenic Cells and Therapeutic Targets in Rheumatoid Arthritis. Semin. Arthritis Rheum.**, 29(1): 27-35.
- Yoshimura, S.; Sakamoto, S.; Kudo, H.; Suzuki, S.; Sassa, S.; Matsubara, M. and Nagasawa, H. (1995):** Effects of danazol on proliferation and viability of 7,12-dimethylbenz (a) anthracene-induced mammary tumours in rats. **Anticancer Res.**, 15(1): 61-65.
- Zhao, G. Z. (1994):** Effects of permanent magnetic field on DNA metabolism of human periodontal ligament fibroblast in vitro. **Chung Hua Kou Chiang.**, 29(2): 75-80.
- Zuker, M. (1989):** Computer prediction of RNA secondary structure. **Meth. Enzym.**, 180: 262-289.
- Zuker, M. (1994):** Prediction of RNA secondary structure by energy minimization. **Meth. Molec. Biol.**, 25: 267-294.